Skip to main content
hello world

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B

Newswire.ca - Thu Oct 26, 2023

CSL's HEMGENIX® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis

OTTAWA, ON, Oct. 26, 2023 /CNW/ -- Global biotechnology leader CSL (ASX: CSL) today announced that Health Canada has authorized HEMGENIX® (etranacogene dezaparvovec), the first and only gene therapy for the treatment of hemophilia B. HEMGENIX is indicated for the treatment of adults with hemophilia B who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. There is no clinical experience of HEMGENIX use in patients with mild or moderate hemophilia B (FIX activity >2%).

Read more at newswire.ca